Servier is an international pharmaceutical company headquartered in Suresnes, France. It was founded in 1954 and operates as a private group governed by a non-profit foundation.
Servier agreed to acquire Day One for $2.5B, gaining an approved childhood brain tumor drug and pipeline assets. SCRI and MSD launched a collaboration to expand community oncology trial access, while Recursion took full ownership of REC-102 as Nvidia and Novo exited.
Servier will acquire Edgewise Therapeutics' muscular dystrophy business, including the drug sevasemten, for up to $2.65 billion. Sevasemten recently faced an FDA rejection for accelerated approval in Becker muscular dystrophy but is advancing to a Phase 3 trial in 2026. The drug has received multiple FDA and EMA designations for both Becker and Duchenne muscular dystrophy.
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07722312 |
S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07719348 |
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07259733 |
Rapid Management of Resistant Hypertension in the Public Health System (Fast Control) |
RECRUITING | NA |
| NCT07071844 |
BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients |
NOT_YET_RECRUITING | PHASE2 |
| NCT07028424 |
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment |
NOT_YET_RECRUITING | PHASE2 |
| NCT06780930 |
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06707493 |
Ivosidenib as Post-HSCT Maintenance for AML |
RECRUITING | PHASE2 |
| NCT06464276 |
Effectiveness and Tolerability of Trimetazidine 80mg Once Daily in Patients With Chronic Coronary Syndrome: The V-GOOD Study |
COMPLETED | |
| NCT06245356 |
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer |
RECRUITING | PHASE2 |
| NCT06081829 |
A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation |
ACTIVE_NOT_RECRUITING | PHASE2 |
